Eton Pharmaceuticals (NASDAQ:ETON) Q3 2021 Earnings Conference Call November 15, 2021 4:30 PM ET Company Participants David Krempa – Senior Vice President-Business Development and Investor Relations Sean Brynjelsen – Chief Executive Officer Wilson Troutman – Chief Financial Officer Conference Call Participants Boobalan Pachaiyappan – H.C. Wainwright Operator Good afternoon and welcome to the Eton Pharmaceuticals’ Third Quarter 2021 Financial and Operating Results Conference Call. At this time, all participa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________ Commission file number: 001-38738 ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its ch ...

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q2 2021 Results Conference Call August 16, 2021 4:30 PM ET Company Participants David Krempa - SVP, Business Development and IR Sean Brynjelsen - CEO Wilson Troutman - CFO Paul Stickler - SVP, Sales and Marketing Conference Call Participants Andrew D’silva - B. Riley Securities Ram Selvaraju - H.C. Wainwright Operator Good afternoon and welcome to the Eton Pharmaceuticals Second Quarter 2021 Financial and Operating Results Conference Call. At this time, all participa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________ Commission file number: 001-38738 ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________ Commission file number: 001-38738 ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its ch ...

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2020 Earnings Conference Call March 16, 2021 4:30 PM ET Company Participants David Krempa - Vice President, Business Development Sean Brynjelsen - Chief Executive Officer Wilson Troutman - Chief Financial Officer Paul Stickler - Senior Vice President, Sales and Marketing Conference Call Participants Andrew D’silva - B. Riley Securities Ram Selvaraju - H.C. Wainwright Operator Good afternoon and welcome to the Eton Pharmaceuticals Fourth Quarter 2020 Financial and ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.001 par value ETON The Nasdaq Global Market FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ______ TO Commission ...

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q3 2020 Earnings Conference Call November 12, 2020 4:30 PM ET Company Participants David Krempa - Vice President of Business Development Sean Brynjelsen - Chief Executive Officer Paul Stickler - Senior Vice President of Sales & Marketing Conference Call Participants Andrew D'silva - B.Riley FBR Operator Good afternoon and welcome to the Eton Pharmaceuticals Third Quarter 2020 Financial and Operating Results Conference Call. At this time, all participants are in a lis ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________ Commission file number: 001-38738 ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in it ...

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q2 2020 Earnings Conference Call August 12, 2020 4:30 PM ET Company Participants David Krempa – Vice President of Business Development Sean Brynjelsen – Chief Executive Officer Paul Stickler – Senior Vice President of Sales and Marketing Wilson Troutman – Chief Financial Officer Conference Call Participants Ram Selvaraju – H.C. Wainwright Andrew D’silva – B.Riley FBR Brooks O'Neil – Lake Street Capital Operator Good afternoon, and welcome to Eton Pharmaceuticals Seco ...